ArticleClinical and translational medicine2021
Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry.
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Review
- Characterization of immune phenotypes in peripheral blood of adult renal transplant recipients using mass cytometry (CyTOF).ImmunoHorizons · 2025Article
- Engineering a solution for allogeneic CAR-T rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Donor and recipient hematopoietic stem and progenitor cells mobilization in liver transplantation patients.Stem cell research & therapy · 2024Article
- Dynamic immune recovery process after liver transplantation revealed by single-cell multi-omics analysis.Innovation (Cambridge (Mass.)) · 2024Article
- Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Immune Checkpoints in Solid Organ Transplantation.Biology · 2023Review
- Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.Scientific reports · 2023Observational
- Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia.International journal of biological sciences · 2023Article
- Revisiting transplant immunology through the lens of single-cell technologies.Seminars in immunopathology · 2023Review
- Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry.Clinical and translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Tacrolimus (FK506) and rapamycin (RAPA) are widely used to maintain long-term immunosuppression after organ transplantation. However, the impact of accumulative drug administration on the recipients' immune systems remains unclear. We investigated the impact of 3-year FK506 or RAPA treatment after renal transplantation on the human immune systems. A discovery cohort of 30 patients was first recruited, and we discovered two distinctive T lineage suppressive regulatory patterns induced by chronic treatment of FK506 and RAPA. The increased percentage of senescent CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.